Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518.
Ann Oncol. 2019.
PMID: 30475947
Free article.
Clinical Trial.